Molecular Imaging Core Unit

Home | Research & Innovation | Scientific Programmes | Biotechnology Programme | Molecular Imaging Core Unit


  • Guillermo Garaulet
  • Guillermo Medrano
  • David Sabador

A new strategy involving molecular imaging is Theranostics, which integrates diagnostics and therapy for patient management. In the oncology field, this technique combines tumour diagnostic imaging and therapeutics, trying to improve existing techniques. The possibility of detecting the disease, guiding therapy and conducting follow-up is opening a new chapter in precision medicine.

In molecular imaging medicine, theranostics refers to the use of molecules labelled with either diagnostic radionuclides (e.g. gamma-ray or positron emitters) or with therapeutic radionuclides (beta-particle emitters) for diagnosis and treatment of a particular disease. Thus, molecular imaging and disease diagnosis can effectively lead to personalised treatment using the same study molecules.